Hyperpigmentation, such as melasma, postinflammatory melanoderma and dermatitis caused by increased production and accumulation of melanin are the major problems today. Ascorbyl Palmitate (AP) and Sodium Ascorbyl Phosphate (SAP), derivatives of ascorbic acid, having the inhibitory effect on skin melanin production and also has anti-inflammatory activity. Aim of this study was to investigate the synergistic effects of ascorbyl palmitate and sodium ascorbyl phosphate loaded in three multiple emulsion formulations i.e. ME1, ME2, and ME3 on facial skin melanin and erythema contents of Asian human females over 12-week treatment course. Thirty three female volunteers were enrolled to singleblinded, placebo-controlled, split-face trial, 3 groups of 11 volunteers each were treated with active treatments versus control/placebo for a period of 12 weeks. Evaluation was performed with non-invasive bioengineering techniques. Patch testing showed no side effects. Control multiple emulsion showed insignificant results while active multiple emulsion formulations showed a significant decrease in skin melanin and erythema content after statistically applied ANOVA (p <0.05). Ascorbyl palmitate and sodium ascorbyl phosphate are potent antioxidants. Treatments of human skin with active formulations; ME1, ME2, and ME3 containing Ascorbyl palmitate and sodium ascorbyl phosphate significantly reduces facial skin melanin and erythema thus could be explored further for the treatment of pigmentation disorders and dermatitis.